Please login to the form below

Not currently logged in
Email:
Password:

TxCell

This page shows the latest TxCell news and features for those working in and with pharma, biotech and healthcare.

Sangamo bulks up in cell therapy with TxCell acquisition

Sangamo bulks up in cell therapy with TxCell acquisition

Hopes to start cell-based immunotherapy trials next year. Sangamo has agreed a 72m deal to take control of French biotech TxCell, eyeing a regulatory T cell (Treg) platform that it ... By acquiring TxCell, Sangamo thinks it will be able to start trials

Latest news

  • TxCell plans listing as EU biotech wakes up to IPOs

    Move follows UK allergy therapy developer Circassia's listing. The return of the biotech initial public offering (IPO) in 2013 was largely a US phenomenon, but France's TxCell is flying ... Ferring is paying 3m upfront for rights to Ovasave, and will be

More from news
Approximately 2 fully matching, plus 0 partially matching documents found.

Latest Intelligence

  • Deal Watch table for March 2014 Deal Watch table for March 2014

    138.5. TxCell/ Ferring. Collaboration, option,  licence. Ovasave - personalised cell-based immunotherapy for IBD (inc Crohn's disease, ulcerative colitis) (p2).

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest appointments

  • Zelluna appoints Miguel Forte as CEO Zelluna appoints Miguel Forte as CEO

    Prior to his new role, Forte has held roles for Bone Therapeutics, TxCell, the European Medicines Agency, and  UCB to name a few.

  • Bone Therapeutics strengthens clinical development team Bone Therapeutics strengthens clinical development team

    Forte arrives at Bone Therapeutics with over 20 years of industry experience, most recently as chief operating and medical officer at TxCell and before that as chair of the commercialisation committee

  • TxCell appoints François Myer as executive chairman TxCell appoints François Myer as executive chairman

    French biotech company TxCell has appointed François Meyer as its executive chairman as it completes a strategic realignment around its CAR-Treg research programmes. ... Stéphane Boissel, CEO of TxCell, said: “TxCell has now completed its strategic

  • Dr Li Zhou joins TxCell as cell engineering VP Dr Li Zhou joins TxCell as cell engineering VP

    Brings experience from Novartis and ZMKS. Valbonne, France-based biotech TxCell has appointed Dr Li Zhou as vice president of cell engineering with its research department. ... François Meyer, head of research at TxCell, said: “With this key

  • TxCell appoints global scientific advisory board TxCell appoints global scientific advisory board

    French biotechnology firm TxCell has appointed Prof Zelig Eshar, Prof Chiara Bonini and Dr Bernard Malissen to its newly-formed scientific advisory board. ... As members of the board, they will be responsible for monitoring and guiding the research and

More from appointments
Approximately 3 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Bedrock Healthcare Communications

Bedrock Healthcare Communications is a privately owned, award winning communications agency that creates and delivers highly effective, insight driven medical...

Latest intelligence

Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....

Infographics